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circulating numbers of CD34 cells was a better predictor of
successful mobilization than WBC. Our observation that 3/3 pa-
tients who had 5-10 CD34 cells/ul were also successfully col-
lected suggests that it may be possible to lower the start of collec-
tion to when the CD34 count is 	5/ul.
495
HEART SUCCESS WITH BLOOD AND MARROW TRANSPLANT PATIENTS:
A MULTIDISCIPLINARY APPROACH FOR CONGESTIVE HEART FAILURE
PATIENTS
Meyers, A.L., Kulma, A., Johnston, P., Woods, M., Fadol, A. M. D.
Anderson Cancer Center, Houston, TX.
By 2010, it is estimated that the American population aged 65 or
older will increase to over 40 million individuals. This will result in
an increase in the average age of the Blood and Marrow Transplant
population. Increased age translates into co- morbid conditions
that contribute to a signiﬁcant proportion of morbidity and mor-
tality. One example of this includes cardiovascular conditions that
patients bring with them at an increasing rate as they advance in
age. The average rates of cardiovascular events rise from 7 per
1000 men ages 35-44 to 68 per 1000 men ages 85-94 with nar-
rowing gaps with advancing age, and comparable rates occur 10
years later in life for women. Congestive heart failure (CHF) is one
of those cardiovascular co-morbid conditions that this patient pop-
ulation continues to bring into the transplant setting or is devel-
oped as a result of treatment. CHF affects 1.5-2% of the popula-
tion and increases 6-10% in people greater than 65 years of age. In
2003, more than 400 patients were hospitalized at the comprehen-
sive cancer center with a discharge diagnosis of CHF totaling a cost
of 36 million dollars. Cancer patients with heart failure can have
improved clinical outcomes. To improve clinical outcomes of these
patients, we have teamed together with Cardiology and have im-
plemented a Heart Success Program on the 52-bed inpatient unit.
The program entails education of the staff and patients about the
symptoms of CHF, the importance of daily weights, medications,
walking, energy conservation, and nutrition. The program is a
multidisciplinary approach including Pharmacy, APNs, Nursing,
Rehabilitation Services, Social work, Case Management, and Nu-
trition. The goals for the staff utilizing the heart success program
include increasing nurses’ awareness of the pathophysiology and
pharmacology of CHF, being more proactive in its recognition,
and identifying patients eligible for the program. The overall goals
are to have a reduction in hospital admissions for heart failure
exacerbation, decrease the length of stay and healthcare dollars
spent. Weekly rounds are conducted with Cardiology to review the
CHF patients. A case will be presented.
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CLINICAL NURSE RESOURCE: A NEW ROLE DESIGNED TO SUPPLE-
MENT VACANT CLINICAL NURSE SPECIALIST POSITIONS
Johnston, P.A., Meyers, A., Rivera, Z., Causton, C., Davis, L. The
University of Texas M. D. Anderson Cancer Center, Houston, TX.
Clinical Nurse Specialists (CNS) perform a critical role in lead-
ing efforts to improve outcomes affecting the oncology patient.
Through direct intervention, promotion of clinical assessment
skills, critical thinking, advanced clinical skills, and knowledge, and
interactions with the interdisciplinary team, the CNS works to
advance oncology nursing practice as direct care providers, con-
sultants, educators, patient, and system advocates, team coordina-
tors, program designers, and/or researchers. With the downsizing
of the CNS role in hospital and institutional settings, this has led
to a steady decline in the number of applicants entering CNS
academic programs. As a result, institutions that value the CNS
role, and the expertise they provide in highly complex patient care
environments, have experienced long-standing vacancies. Due to
the inability to ﬁll two vacant CNS positions on the Blood and
Marrow Transplant Unit (BMT), a method was undertaken to
identify and recognize experienced clinical nurses who could prac-
tice as unit resources and contribute to the mentoring, support, and
development of patient care providers and evidence-based quality
indicators on the inpatient unit. The Clinical Nurse Resource
(CNR) position was developed to address this need. A position
description including essential functions in clinical practice, edu-
cation, collaboration/consultation, research/quality improvement,
and leadership was formulated. Performance criteria in clinical
practice included serving as a clinical expert in BMT and promot-
ing excellence in clinical nursing practice through assessment and
interaction with staff and the interdisciplinary team. Education
incorporated providing educational opportunities to develop and
enhance performance, problem-solving, and critical thinking. Col-
laboration/consultation involved collaborating and consulting with
the interdisciplinary team to improve patient care delivery. Re-
search included the identiﬁcation and participation in researchable
patient problems or clinical inquiry projects. Outcomes of the
CNR positions were documented on a developed evaluation tool.
Value of the CNR position was immediately achieved with signif-
icant positive outcomes. Some of these included mentorship/
coaching of new BMT clinical staff and an evidence-based research
project to reduce the incidence of falls on the unit. The CNR
position on the inpatient BMT unit has proven to be beneﬁcial as
an alternative to fulﬁll the desired role of the CNS.
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UNMASK THE PEDIATRIC ALLOGENEIC TRANSPLANT PATIENT: A SIN-
GLE CENTER’S EXPERIENCE ON THE USE OF FLUCONAZOLE FOR
ANTIFUNGAL PROPHYLAXIS IN PATIENTS NOT USING FACE MASKS
POST TRANSPLANT
Gourde, J.A., Trotz, B.A., Henry, N., Rodriguez, V., Khan, S. Mayo
Eugenio Litta Children’s Hospital, Rochester, MN.
Many transplant centers require pediatric hematopoietic alloge-
neic transplant patients to wear a face mask until day 100 or
longer. Unlike most transplant centers, our allogeneic recipients
are not required to wear a face mask post-transplant. Our experi-
ence indicates that with the use of ﬂuconazole as standard antifun-
gal prophylaxis it is not necessary to require our patients to wear
face masks post-transplant. Fluconazole (Diﬂucan) dosed at 3-5
mg/kg daily is started on the day of admission pre-transplant and
discontinued once ANC 	 500 times 3 days (engraftment). Pa-
tients with graft-versus-host disease (GVHD) continue to receive
antifungal prophylaxis with ﬂuconazole while on immunosuppres-
sive therapy. We conducted a retrospective chart review of 22
pediatric allogeneic hematopoietic cell transplant (HCT) patients
from 1999-2004, which revealed no reported occurrences of fungal
infections. The patients were treated prophylactically with Diﬂu-
can. Four patients were changed to Ambisome due to recurrent
fevers with negative cultures, and 1 was changed due to interaction
between Diﬂucan and Tacrolimus. Patients were not required to
wear a face mask post-transplant. Therefore, we can speculate that
not wearing a mask does not increase the risk of fungal infections
in pediatric allogeneic HCT. Cases need to be evaluated on an
individual basis, including risk factors and conditioning regimens.
We advocate for larger studies to be completed regarding this
topic.
498
THE BLOOD AND MARROW TRANSPLANTATION BUSINESS CENTER
THAT MAKES A DIFFERENCE IN THE PROCESSING OF BMT PATIENTS
Hontiveros, R.L., Cruz, E.D., Adornetto-Garcia, D. UT M. D. Ander-
son Cancer Center, Houston, TX.
The complexity of the Blood and Marrow Transplantation
(BMT) ﬁnancial process is usually a challenging hurdle for patients
during their treatment. At one of the largest transplant centers in
the country, a multidisciplinary team has developed a process that
enables patients to navigate this aspect of their treatment with ease.
The BMT Business Center (BC) was created to secure autho-
rization for transplantation from insurance companies. The ﬁ-
nancial process covers referrals and consultation from point of
access to admission. To accomplish this, each BC team member
has expertise in their role and is accountable for their portion of
the process. The BC is composed of a Patient Access Supervisor,
a Patient Access Appeals/Denials Coordinator (PADAC), and 4
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